Alkermes(ALKS.US)

Last Updated 19:00:00 ET
longbridge loading

Alkermes reports encouraging data from Phase III study of Lumryz

WorldPharmaceuticals·
US
ALKS
-0.51%
US
LABU
-2.35%
US
BBH
+0.68%
WorldPharmaceuticals·
US
ALKS
-0.51%
US
LABU
-2.35%
US
BBH
+0.68%

Wells Fargo Sticks to Its Buy Rating for Alkermes (ALKS)

Tip Ranks·
US
ALKS
-0.51%
Tip Ranks·
US
ALKS
-0.51%

Sector Update: Healthcare Stocks Advance Late Afternoon

Fidelity·
US
ALKS
-0.51%
US
RDY
-1.10%
US
WST
-0.16%
Fidelity·
US
ALKS
-0.51%
US
RDY
-1.10%
US
WST
-0.16%

Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles

benzinga_article·
US
ALKS
-0.51%
US
FBT
+0.54%
US
IBB
+0.10%
benzinga_article·
US
ALKS
-0.51%
US
FBT
+0.54%
US
IBB
+0.10%

Sector Update: Healthcare Stocks Gain in Afternoon Trading

Fidelity·
US
AGIO
-1.70%
US
ALKS
-0.51%
Fidelity·
US
AGIO
-1.70%
US
ALKS
-0.51%

Alkermes’ Lumryz, from $2.4B Avadel buy, hits phase 3 mark in IH

Fiercepharma·
US
ALKS
-0.51%
US
JAZZ
+3.44%
Fiercepharma·
US
ALKS
-0.51%
US
JAZZ
+3.44%

Alkermes Phase 3 Trial Meets Primary Endpoint for Hypersomnia Treatment

Fidelity·
US
ALKS
-0.51%
Fidelity·
US
ALKS
-0.51%
© 2026 Longbridge｜Disclaimer